News

Windtree Therapeutics is in a phase 2 clinical trial for its investigational therapy, Lucinactant, which produces a synthetic surfactant being studied for acute lung injury in patients with COVID-19 and acute respiratory distress syndrome (ARDS).

A discussion on the pros and cons of frequent, rapid testing in the community.

Cue Health's test is over the counter (OTC) and can be utilized at home.

Hyper-induction of pro-inflammatory cytokines is one of the key aspects of SARS-CoV-2.

Molecular tools like RNA-activated RNases could be a potential new paradigm for therapeutics.

The Luminex test will be able to detect influenza and COVID-19.

One month after the Food and Drug Administration (FDA) approval of monthly rilpivirine/cabotegravir (Cabenuva) for HIV, Janssen has submitted evidence of efficacy with dosing every 2 months.

By integrating genomic and temporal data, 409 viral clusters within 292 care homes were identified.

Neurotropic capacities of SARS-CoV-2 makes it a potent factor to cause acute and late neurological effects.

The findings underscore the connection between COVID-19 and the increased risk from obesity.

Investigators have discovered active substances that can block the replication of coronavirus and may create a pathway for new therapies.

A review of emergency room records showed a very small percentage of patients had acute ischemic strokes, but for those who did, there was an increased risk of requiring long-term care after hospital discharge.

Cells reactive to SARS-CoV-2 peptide pools were found in all anti-NP IgG–positive individuals.

Novel positive controls offer several advantages over the ones currently used in COVID-19 testing.

SARS-CoV-2 infects cardiomyocytes through an ACE2 and endosomal inflammatory infiltrate.

NeuroRx announced results from its phase 2b/3 trial for its investigational therapy, aviptadil, in patients with severe COVID-19.

How pharmacists can use shared decision-making to improve antibiotic use.

The statement comes on the same day as a rare production agreement between pharmaceutical rivals, and Texas' announced lift of spread mitigation measures.

The committee encourages those eligible to receive the vaccine when available to them.

SARS-CoV-2 infection is known to result in a number of extrapulmonary manifestations.

Investigational therapy, ibrexafungerp, from Scynexis is being studied for fungal infections and is moving closer towards a goal of FDA approval later this year.

The Biden Administration is set to announce the deal officially about a partnership for the biopharmaceutical companies today.

A research team recently sought to address this by assessing SARS-CoV-2 positivity in students on or after 9 days after an exposure.

A review of approximately 1000 children with multisystem inflammatory syndrome (MIS-C) from SARS-Cov-2 finds low fatality with aggressive treatment.

Beginning this week, the agency is funneling air travelers from 2 African countries to a limited amount of US airports.

Prime Minister Narendra Modi of India receives vaccine as country begins next phase of program.

Courtesy of HCPLive, here's a look at 3 new pandemic talking points covered at the annual allergy and asthma meeting.

The variant, B.1.526, was first found in samples dating back to November.

Symptoms of COVID-19 can persist for months in about a third of cases, including among those with mild illness, a new study confirms.

The VRBPAC voted 22-0 with no abstentions to support the benefit-risk profile associated with Ad26.COV2.S on Friday night.